One-Shot radiation for recurrent prostate cancer: game changer or risky bet?
NCT ID NCT06941363
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a single, very high dose of radiation (17 Gy) to the prostate area in men whose prostate cancer has come back after surgery. The goal is to see if this precise, one-time treatment can control the cancer while reducing side effects. Fifty men will be enrolled, and researchers will track side effects and quality of life for up to 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
single high-dose radiation therapy (17 Gy) to the prostate bed
What this could lead to
If successful, this could offer a shorter, more precise radiation option for men whose prostate cancer returns after surgery, potentially with fewer side effects.
What could go wrong
This is a small, early-phase study with only 50 participants, so results may not apply to everyone. The high single dose may still cause bladder or bowel side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Radiation Oncology, Fondazione IRCCS San Gerardo dei Tintori (University of Milan Bicocca)
RECRUITINGMonza, Italy, 20900, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••